Both Novo Nordisk’s and competitor Eli Lilly’s injectable GLP-1 drugs, Wegovy and Zepbound, have helped transform obesity ...

Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, ...

A significant breakthrough in the weight-loss medication market: the FDA has approved the first GLP-1 pill for obesity ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on ...

Chronic pain teaches you to gamble with yourself. There’s always one more treatment, one more possible cure, one more ...

Discontinuation of GLP-1 receptor agonists before pregnancy or early during pregnancy was tied to more gestational weight and ...